{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T17:35:40Z","timestamp":1778780140807,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","jvir.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Vascular and Interventional Radiology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.jvir.2018.03.020","type":"journal-article","created":{"date-parts":[[2018,6,20]],"date-time":"2018-06-20T00:09:13Z","timestamp":1529453353000},"page":"1061-1067","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Multicenter Phase II Clinical Trial of Sorafenib Combined with Transarterial Chemoembolization for Advanced Stage Hepatocellular Carcinomas (Barcelona Clinic Liver Cancer Stage C): STAB Study"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7605-8434","authenticated-orcid":false,"given":"Yozo","family":"Sato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Nishiofuku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Yasumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuhiro","family":"Nakatsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiro","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihisa","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironao","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Abo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruyuki","family":"Takaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Yamakado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvir.2018.03.020_bib1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1055\/s-0030-1247133","article-title":"Current strategy for staging and treatment: the BCLC update and future prospects","volume":"30","author":"Forner","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jvir.2018.03.020_bib2","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma","volume":"56","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jvir.2018.03.020_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000368141","article-title":"Surveillance and diagnostic algorithm for hepatocellular carcinoma proposed by the Liver Cancer Study Group of Japan: 2014 update","volume":"87","author":"Kudo","year":"2014","journal-title":"Oncology"},{"key":"10.1016\/j.jvir.2018.03.020_bib4","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/j.gastro.2015.12.041","article-title":"Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma","volume":"150","author":"Bruix","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jvir.2018.03.020_bib5","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1053\/j.gastro.2014.02.032","article-title":"Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma","volume":"146","author":"Yau","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jvir.2018.03.020_bib6","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jhep.2016.05.044","article-title":"Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion","volume":"65","author":"Kokudo","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jvir.2018.03.020_bib7","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/cncr.20426","article-title":"Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey","volume":"101","author":"Ikai","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.jvir.2018.03.020_bib8","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jvir.2018.03.020_bib9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jvir.2018.03.020_bib10","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.ejca.2011.05.007","article-title":"Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma","volume":"47","author":"Kudo","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jvir.2018.03.020_bib11","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1002\/ijc.29126","article-title":"The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial","volume":"136","author":"Chao","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jvir.2018.03.020_bib12","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jhep.2016.01.012","article-title":"Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial","volume":"64","author":"Lencioni","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jvir.2018.03.020_bib13","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1200\/JCO.2011.37.1021","article-title":"Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma","volume":"29","author":"Pawlik","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jvir.2018.03.020_bib14","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1148\/radiol.2015142481","article-title":"Open-label single-arm phase II trial of sorafenib therapy with drug-eluting bead transarterial chemoembolization in patients with unresectable hepatocellular carcinoma: clinical results","volume":"277","author":"Cosgrove","year":"2015","journal-title":"Radiology"},{"key":"10.1016\/j.jvir.2018.03.020_bib15","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1148\/radiol.13130150","article-title":"Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses","volume":"269","author":"Choi","year":"2013","journal-title":"Radiology"},{"key":"10.1016\/j.jvir.2018.03.020_bib16","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1148\/radiol.14131946","article-title":"Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib\u2014a retrospective controlled study","volume":"272","author":"Zhu","year":"2014","journal-title":"Radiology"},{"key":"10.1016\/j.jvir.2018.03.020_bib17","doi-asserted-by":"crossref","first-page":"e96620","DOI":"10.1371\/journal.pone.0096620","article-title":"Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study","volume":"9","author":"Hu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jvir.2018.03.020_bib18","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1148\/radiol.2015150667","article-title":"TACE treatment in patients with sorafenib-treated unresectable hepatocellular carcinoma in clinical practice: final analysis of GIDEON","volume":"279","author":"Geschwind","year":"2016","journal-title":"Radiology"},{"key":"10.1016\/j.jvir.2018.03.020_bib19","unstructured":"Vogl TJ, Trojan J, Goller M, et\u00a0al. Evaluation of a combined protocol of sorafenib and transarterial chemoembolization (TACE) vs. TACE vs. sorafenib protocol alone in advanced stage hepatocellular carcinoma (HCC): retrospective study at three German liver centers. Abstract presented at RSNA 2013. December 1\u20136, 2013; Chicago, IL. Abstract SSC16-04."},{"key":"10.1016\/j.jvir.2018.03.020_bib20","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.20933","article-title":"Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma","volume":"42","author":"Bruix","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jvir.2018.03.020_bib21","unstructured":"National Cancer Institute Common Terminology Criteria for Adverse Events v4.0. NCI, NIH, DHHS. May 29, 2009. NIH publication # 09-7473."},{"key":"10.1016\/j.jvir.2018.03.020_bib22","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jvir.2018.03.020_bib23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jvir.2018.03.020_bib24","first-page":"1079","article-title":"How large should a phase II trial of a new drug be?","volume":"71","author":"Simon","year":"1987","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.jvir.2018.03.020_bib25","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00535-016-1173-5","article-title":"Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study","volume":"51","author":"Kaneko","year":"2016","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.jvir.2018.03.020_bib26","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3748\/wjg.v13.i3.414","article-title":"Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma","volume":"13","author":"Uka","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jvir.2018.03.020_bib27","doi-asserted-by":"crossref","first-page":"4475","DOI":"10.1002\/cncr.25960","article-title":"Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors","volume":"117","author":"Uchino","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.jvir.2018.03.020_bib28","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/j.1440-1746.2011.06917.x","article-title":"Role of intrahepatic tumor control in the prognosis of patients with hepatocellular carcinoma and extrahepatic metastases","volume":"27","author":"Jung","year":"2012","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jvir.2018.03.020_bib29","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1440-1746.2010.06341.x","article-title":"Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: does transarterial chemoembolization improve survival in these patients?","volume":"26","author":"Yoo","year":"2011","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jvir.2018.03.020_bib30","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jhep.2012.06.014","article-title":"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial","volume":"57","author":"Bruix","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jvir.2018.03.020_bib31","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.ejca.2011.12.006","article-title":"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial","volume":"48","author":"Cheng","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jvir.2018.03.020_bib32","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma","volume":"35","author":"Lo","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jvir.2018.03.020_bib33","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1007\/s00535-016-1204-2","article-title":"Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON","volume":"51","author":"Kudo","year":"2016","journal-title":"J\u00a0Gastroenterol"}],"container-title":["Journal of Vascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051044318310492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051044318310492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,28]],"date-time":"2019-07-28T22:09:43Z","timestamp":1564351783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1051044318310492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S1051044318310492"],"URL":"https:\/\/doi.org\/10.1016\/j.jvir.2018.03.020","relation":{},"ISSN":["1051-0443"],"issn-type":[{"value":"1051-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multicenter Phase II Clinical Trial of Sorafenib Combined with Transarterial Chemoembolization for Advanced Stage Hepatocellular Carcinomas (Barcelona Clinic Liver Cancer Stage C): STAB Study","name":"articletitle","label":"Article Title"},{"value":"Journal of Vascular and Interventional Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvir.2018.03.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 SIR, 2018","name":"copyright","label":"Copyright"}]}}